Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 141-148

  Smoley, Stephanie A ^a   Van Dyke, Daniel L ^a   Kay, Neil E ^b   Heerema, Nyla A ^c   Dell' Aquila, Marie L ^d   Dal Cin, Paola ^e   Koduru, Prasad ^f   Aviram, Ayala ^f   Rassenti, Laura ^g   Byrd, John C ^c   Rai, Kanti R ^h   Brown, Jennifer R ⁱ   Greaves, Andrew W ^d   Eckel Passow, Jeanette ^a   Neuberg, Donna ^f   Kipps, Thomas J ^d   Dewald, Gordon W ^a  

^a Cytogenetics Division of Laboratory Genetics   (United States)

^b MAYO CLINIC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h LONG ISLAND JEWISH MEDICAL CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ACCURACY; ARTICLE; BLOOD CELL; BONE MARROW CELL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 6Q; CHROMOSOME REARRANGEMENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; STANDARDIZATION; WORKSHOP;

BONE MARROW CELLS; CYTOGENETICS; FALSE NEGATIVE REACTIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDE PROBES; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS;

EID: 78649999975     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.009     Document Type: Article

References (18)

1. Shanafelt T.D. Predicting clinical outcome in CLL: how and why. Hematology Am Soc Hematol Educ Program 2009, 421-429.
2. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
3. Dewald G.W., Brockman S.R., Paternoster S.F., Bone N.D., O'Fallon J.R., Allmer C., et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287-295.
4. Fink S.R., Paternoster S.F., Smoley S.A., Flynn H.C., Geyer S.M., Shanafelt T.D., et al. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res 2005, 29:253-262.
5. Van Dyke D.L., Shanafelt T.D., Call T.G., Zent C.S., Smoley S.A., Rabe K.G., et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2010, 148:544-550.
6. American College of Medical Genetics Standards and guidelines for clinical genetics laboratories Available at:, Accessed on May 1, 2010. http://www.acmg.net/AM/Template.cfm?Section=Laboratory_Standards_and_Guidelines&Template=/CM/HTMLDisplay.cfm&ContentID=5308.
7. Enns R, Dewald G, Barker P, Rasmussen D, Watson M, Wood G, Wyatt P. Fluorescence in situ hybridization (FISH) methods for medical genetics: approved guideline. In: NCCLS document MM7-A [ISBN 1-56238-524-0]. Wayne, PA, 2004.
8. Wiktor A.E., Van Dyke D.L., Stupca P.J., Ketterling R.P., Thorland E.C., Shearer B.M., et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 2006, 8:16-23.
9. Dewald G.W., Stallard R., Bader P.I., Chen K., Zenger-Hain J., Harris C.J., et al. Toward quality assurance for metaphase FISH: a multicenter experience. Am J Med Genet 1996, 65:190-196.
10. Dewald G., Stallard R., Al Saadi A., Arnold S., Bader P.I., Blough R., et al. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes. Am J Med Genet 1998, 76:318-326.
11. Dewald G., Stallard R., Al Saadi A., Arnold S., Blough R., Ceperich T.M., et al. A multicenter investigation with D-FISH BCR/ABL1 probes. Cancer Genet Cytogenet 2000, 116:97-104.
12. Dewald G., Brockman S.R., Paternoster S.F. Molecular cytogenetic studies in hematological malignancies. Hematopathology in Oncology 2004, 69-112. Kluwer Academic Publications, Norwell, MA. W. Finn, L. Peterson (Eds.).
13. Goorha S., Glenn M.J., Drozd-Borysiuk E., Chen Z. A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Genet Med 2004, 6:48-53.
14. Nowakowski G.S., Dewald G.W., Hoyer J.D., Paternoster S.F., Stockero K.J., Fink S.R., et al. Interphase fluorescence in situ hybridization (FISH) with an IGH probe is important in the management of patients with a clinical diagnosis of chronic lymphocytic leukemia (CLL). Brit J Hematol 2005, 130:36-42.
15. Dewald G.W., Therneau T., Larson D., Lee Y.K., Fink S., Smoley S., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005, 106:3553-3558.
16. Dewald G.W., Wyatt W.A., Juneau A.L., Carlson R.O., Zinsmeister A.R., Jalal S.M., et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998, 91:3357-3365.
17. Catovsky D., Richards S., Matute E., Oscier D., Dye M.J.S., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet 2007, 370:230-239. on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinial Studies Group and NCRI Chronic Lymphocytic Leukaemia Working Group.
18. Tam C.S., Shanafelt T.D., Wierda W.G., Abruzzo L., Van Dyke D.L., O'Brien S., et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood 2009, 114:957-964.